Top Markets
Coin of the day
Hemagen Diagnostics, Inc. Hemagen Diagnostics, Inc.

Hemagen Diagnostics, Inc.

HMGN
Rang in aandelen #42231
Hemagen Diagnostics, Inc., a global biotechnology firm, specializes in... Hemagen Diagnostics, Inc., a global biotechnology firm, specializes in delivering clinical diagnostic solutions for both human and animal health. The company designs, manufactures, and distributes the VIRGO product line, a series of human clinical immunoassays used for identifying autoimmune and infectious diseases, as well as acute phase proteins. Its comprehensive human diagnostic portfolio also encompasses Universal IFA components, various supplies, controls, calibrators, accessories, H-rotors, reagents, electrodes, equipment, and specialized assays covering conditions such as Chagas, acute phase proteins, and cytokines. For the veterinary market, Hemagen Diagnostics provides diagnostic equipment, reagents, consumables, accessories, and electrodes crucial for chemistry, hematology, and electrolyte analysis. The company reaches a diverse customer base, including laboratories, hospitals, and blood banks, through both direct sales and an extensive distribution network. Established in 1985, Hemagen Diagnostics maintains its headquarters in Columbia, Maryland.
Aandeelprijs
$0.0002
Laatst gesynchroniseerd: 2026-08-11
Marktkapitalisatie
$3.10K
Verandering (1 dag)
0.00%
Verandering (1 jaar)
100.00%
Land
US
Handel Hemagen Diagnostics, Inc. (HMGN)

Categorie

P/B-ratio voor Hemagen Diagnostics, Inc. (HMGN)
P/B-ratio op 2026 TTM: 0
Volgens de meest recente financiële rapporten en aandelenkoers van Hemagen Diagnostics, Inc. is de huidige P/B-ratio (TTM) 0. Eind 2026 had het bedrijf een P/B-ratio van 0.
P/B-ratiohistoriek voor Hemagen Diagnostics, Inc. van 2026 tot 2026
P/B-ratio aan het einde van elk jaar
Jaar P/B-ratio Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
P/B-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/B-ratio Verschil in P/B-ratio Land
6.2613 -
US
6.3483 -
NL
- -
CH
3.634 -
BE
- -
KR